William Blair analyst Myles Minter last night initiated coverage of Argenx with an Outperform rating and $460.66 fair value estimate. Argenx is a leading commercial-stage biopharma company developing novel therapies for rare autoimmune disorder, Minter tells investors in a research note. The analyst believes Vyvgart is a "best-in-class product with a first-mover advantage over peers." He "conservatively" estimates $2.8B in peak sales for the generalized myasthenia gravis indication alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- Argenx initiated with an Outperform at William Blair
- Argenx price target raised to EUR 450 from EUR 405 at Barclays
- Argenx to acquire PRV for $102M
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review